[Histologic occurrence of Barrett's carcinoma].

Hiroyuki Naitoh(Shiga University of Medical Science), Masaya Hosokawa, H. Tamura, Eiji Mekata, A. Kawaguchi, Makoto Kodama, Tetsuo Tani(Keio University)

PubMed

March 1, 1999

Cited by 0

Related Papers

<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer

|Oncotarget|2015|159

MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer

|Cancer Cell|2022|101

<i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity

|Cancer Discovery|2024|98

Activation of Tumor-Cell STING Primes NK-Cell Therapy

|Cancer Immunology Research|2022|88

Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer

|Molecular Cancer Research|2016|73